Cargando…
Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests
High-throughput screening (HTS) is one of the newest techniques used in drug design and may be applied in biological and chemical sciences. This method, due to utilization of robots, detectors and software that regulate the whole process, enables a series of analyses of chemical compounds to be cond...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269696/ https://www.ncbi.nlm.nih.gov/pubmed/22312262 http://dx.doi.org/10.3390/ijms13010427 |
_version_ | 1782222494986403840 |
---|---|
author | Szymański, Paweł Markowicz, Magdalena Mikiciuk-Olasik, Elżbieta |
author_facet | Szymański, Paweł Markowicz, Magdalena Mikiciuk-Olasik, Elżbieta |
author_sort | Szymański, Paweł |
collection | PubMed |
description | High-throughput screening (HTS) is one of the newest techniques used in drug design and may be applied in biological and chemical sciences. This method, due to utilization of robots, detectors and software that regulate the whole process, enables a series of analyses of chemical compounds to be conducted in a short time and the affinity of biological structures which is often related to toxicity to be defined. Since 2008 we have implemented the automation of this technique and as a consequence, the possibility to examine 100,000 compounds per day. The HTS method is more frequently utilized in conjunction with analytical techniques such as NMR or coupled methods e.g., LC-MS/MS. Series of studies enable the establishment of the rate of affinity for targets or the level of toxicity. Moreover, researches are conducted concerning conjugation of nanoparticles with drugs and the determination of the toxicity of such structures. For these purposes there are frequently used cell lines. Due to the miniaturization of all systems, it is possible to examine the compound’s toxicity having only 1–3 mg of this compound. Determination of cytotoxicity in this way leads to a significant decrease in the expenditure and to a reduction in the length of the study. |
format | Online Article Text |
id | pubmed-3269696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-32696962012-02-06 Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests Szymański, Paweł Markowicz, Magdalena Mikiciuk-Olasik, Elżbieta Int J Mol Sci Review High-throughput screening (HTS) is one of the newest techniques used in drug design and may be applied in biological and chemical sciences. This method, due to utilization of robots, detectors and software that regulate the whole process, enables a series of analyses of chemical compounds to be conducted in a short time and the affinity of biological structures which is often related to toxicity to be defined. Since 2008 we have implemented the automation of this technique and as a consequence, the possibility to examine 100,000 compounds per day. The HTS method is more frequently utilized in conjunction with analytical techniques such as NMR or coupled methods e.g., LC-MS/MS. Series of studies enable the establishment of the rate of affinity for targets or the level of toxicity. Moreover, researches are conducted concerning conjugation of nanoparticles with drugs and the determination of the toxicity of such structures. For these purposes there are frequently used cell lines. Due to the miniaturization of all systems, it is possible to examine the compound’s toxicity having only 1–3 mg of this compound. Determination of cytotoxicity in this way leads to a significant decrease in the expenditure and to a reduction in the length of the study. Molecular Diversity Preservation International (MDPI) 2011-12-29 /pmc/articles/PMC3269696/ /pubmed/22312262 http://dx.doi.org/10.3390/ijms13010427 Text en © 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Szymański, Paweł Markowicz, Magdalena Mikiciuk-Olasik, Elżbieta Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests |
title | Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests |
title_full | Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests |
title_fullStr | Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests |
title_full_unstemmed | Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests |
title_short | Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests |
title_sort | adaptation of high-throughput screening in drug discovery—toxicological screening tests |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269696/ https://www.ncbi.nlm.nih.gov/pubmed/22312262 http://dx.doi.org/10.3390/ijms13010427 |
work_keys_str_mv | AT szymanskipaweł adaptationofhighthroughputscreeningindrugdiscoverytoxicologicalscreeningtests AT markowiczmagdalena adaptationofhighthroughputscreeningindrugdiscoverytoxicologicalscreeningtests AT mikiciukolasikelzbieta adaptationofhighthroughputscreeningindrugdiscoverytoxicologicalscreeningtests |